Neupro(R) Filed With The FDA For The Treatment Of Restless Legs Syndrome

UCB announced that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as a treatment for moderate-to-severe restless legs syndrome (RLS) has been accepted for filing by the U.S. Food and Drug Administration (FDA). Neupro(R) is a once-daily patch designed to provide continuous drug delivery over a 24 hour period. Restless Legs Syndrome is a chronic neurological disorder that affects between three and ten per cent of the population. [click link for full article]

More: continued here

Filed under: Neurology / Neuroscience on December 15th, 2007